• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs

September 23, 2021 by David Barret Leave a Comment

September 23, 2021

By Alistair Smout

LONDON (Reuters) – AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.

Under the deal, VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.

AstraZeneca already produces an adenoviral vector COVID-19 vaccine, and emphasised the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programmes beyond the coronavirus pandemic.

“This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox,” said AstraZeneca research chief Mene Pangalos.

The technology works in a similar way to the messenger RNA (mRNA) vaccines made by Pfizer/BioNTech and Moderna.

However, a self-amplifying RNA vaccine not only encodes the instructions for the host cell to make a coronavirus protein, but makes lots of copies of the RNA containing those instructions, meaning doses can be smaller and cheaper.

“It’s a bit like having a manufacturing facility, and instead of having one copy of the recipe, you have multiple copies that you can hand round to multiple production lines within the cell to produce more protein,” Imperial’s Shattock told Reuters. “So that’s why it has that opportunity to use lower doses.”

Imperial’s COVID-19 vaccine is being retooled to produce a more consistent immune response with an eye on future coronavirus variants.

AstraZeneca, under the deal, has the option to collaborate on 26 drug targets for use against other therapeutic areas like cancers and rare genetic diseases.

“We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest,” Pangalos said.

U.S. companies Gritstone bio and Arcturus also are developing saRNA COVID-19 vaccines.

Shattock said safety data had been encouraging from initial trials of its COVID-19 vaccine, released in July ahead of peer review, and that Phase I results of its refined vaccine would be ready early next year.

“The reason we were slower was because we were coming from an academic setting,” he said. “If we had this relationship (with AstraZeneca) at the beginning of 2020, we might have been faster.”

(Reporting by Alistair Smout; Additional reporting by Christine Soares; Editing by Bill Berkrot)

Source Link AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs

David Barret
David Barret

Related posts:

  1. Hunted by the men they jailed, Afghanistan’s women judges seek escape
  2. ‘Stagflation’ trades boom as investors flee U.S. debt
  3. Over 40% of UK companies face recruitment difficulties – ONS
  4. Concreit closes on $6M to allow more people to invest in the global private real estate market

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Dangerous Radiation Awaits Astronauts On Mars – New Mission Could Work Out Just How Much
  • A 4.9 Million-Year-Old Ecosystem Of Interconnected Worlds Is Preserved In A Tennessee Sinkhole
  • 100 Years Since The Scopes (Monkey) Trial: How Much Has Changed Since America’s “Trial Of The Century”?
  • Elephants Use All Kinds Of Gestures To Communicate – They Just Want Apples
  • NASA’s Parker Solar Probe Finds Evidence Of “Barrier” In The Sun’s 2 Million Kelvin Atmosphere
  • Watching Videos At Higher Speeds May Save Time But It Has Some Drawbacks
  • In 2008, Ukraine’s Space Agency Sent A Message To Planet Gliese 581c. It Will Arrive In 2029
  • In A First, A Robot Listened To Spoken Instructions And Performed Surgery – Just Like A Human Would
  • Newly Discovered “Bone-Digesting” Cells Help Burmese Pythons Consume Every Last Bit Of Their Prey
  • Gold Can Be Made By Scientists In A Lab – There’s Just One Problem
  • Recovery Of 24-Million-Year-Old Protein Fragments From Extinct Animal Opens “New Chapter” Of Biology
  • 6 Leading Medical Organizations Team Up To Sue RFK Jr Over COVID-19 Vaccine Policy
  • Less Ice, More Fire: Evidence Melting Glaciers Make Volcanic Eruptions More Explosive
  • This Mini Fridge-Sized Spacecraft Could Study A Time Of The Universe We’ve Never Seen Before
  • Psilocybin Shows Potential In Slowing Human Cell Aging And Increasing Lifespan In Mice
  • Blue Sharks’ Freaky Tooth-Skin Makes It Possible For Them To Change Color To Green And Even Gold
  • Summer In The Northern Hemisphere Will Be 15 Minutes Shorter Than Last Year’s
  • Your Ability To Be Funny May Not Be Inherited After All, And That’s Really Unexpected
  • New Interstellar Comet Tracked To Its Origin Region: “It’s Much Older Than The Solar System”
  • ChatGPT Gets “Absolutely Wrecked” By An Atari Video Chess Game Built In 1979
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version